Despite the observed increase in heart rate, several meta-analyses have demonstrated that GLP-1RAs are associated with a lower risk of AF compared with other glucose-lowering agents, suggesting their potential protective effect against AF occurrence (131, 148)
Provider evaluation is essential to identify which drug classor neithersuits each patient's medical and psychiatric history, comorbidities, and treatment goals
A FAERS-based pharmacovigilance analysis comparing tirzepatide vs semaglutide in female reports (Q1 2022Q3 2025) reported gynaecological haemorrhagic events in 0.62% of semaglutide cases (204 cases among 32,839 female-specific reports in that analysis) and did not detect a disproportionate signal vs tirzepatide
Additionally, one study reported increased dysgeusia (loss of taste), throat tightness and irritation, dysphagia (difficulty swallowing), and dysphonia (difficulty speaking) ( Khan et al
Since distribution of GLP-1R in the kidney remains controversial, the renoprotective effects of GLP-1RAs may be partially explained by this mechanism
